Form 4: uniQure Director Robert Gut Executes Stock Transactions

Director Robert Gut exercised stock options and sold shares of uniQure N.V. as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Robert Gut exercised options for 2,645 ordinary shares at a strike price of $16.04.
• The director subsequently sold 7,552 shares across multiple transactions on June 10, 2026, at prices ranging from $26.01 to $26.53.
• An additional 2,726 shares were sold on June 11, 2026, at a weighted average price of $27.06 to cover tax withholding obligations.
• The director was granted 7,550 restricted share units (RSUs) and 13,980 new stock options with an exercise price of $26.82.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine administrative actions related to equity compensation and pre-planned tax management.

Positives

• Transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
• The director maintains a significant beneficial ownership of 32,259 ordinary shares following these transactions.

Negatives

• The filing reflects a net reduction in direct share ownership by the director following the exercise and sale activity.

Risks

• Future vesting of restricted share units and options is contingent upon the director's continued relationship with the issuer.

Future Outlook

The director received 7,550 restricted share units and 13,980 stock options, both of which vest on the first anniversary of the grant date, contingent on continued service.

Management Comments

• Transactions were effected pursuant to a sales plan adopted on July 8, 2025, intended to comply with Rule 10b5-1.
• Sales on June 11, 2026, were executed solely to cover estimated withholding taxes upon the vesting of restricted share units.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard practice in the biotechnology sector, often used by executives to manage personal liquidity and tax obligations without signaling a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a best-practice standard for corporate insiders to avoid potential allegations of trading on material non-public information.
• The volume of shares sold is consistent with typical director compensation and tax-planning cycles observed in mid-cap biotech firms.

Stakeholder Impact

• Shareholders should view these transactions as routine liquidity events rather than a change in corporate strategy or outlook.

Next Steps

• Vesting of 7,550 restricted share units on June 10, 2027.
• Vesting of 13,980 stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, insider trading, Form 4, biotech, equity compensation